1. Home
  2. CYTH vs NTIP Comparison

CYTH vs NTIP Comparison

Compare CYTH & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • NTIP
  • Stock Information
  • Founded
  • CYTH 1990
  • NTIP 1990
  • Country
  • CYTH United States
  • NTIP United States
  • Employees
  • CYTH N/A
  • NTIP N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • NTIP Multi-Sector Companies
  • Sector
  • CYTH Health Care
  • NTIP Miscellaneous
  • Exchange
  • CYTH Nasdaq
  • NTIP Nasdaq
  • Market Cap
  • CYTH 35.5M
  • NTIP 37.5M
  • IPO Year
  • CYTH N/A
  • NTIP 1998
  • Fundamental
  • Price
  • CYTH $1.15
  • NTIP $1.65
  • Analyst Decision
  • CYTH Strong Buy
  • NTIP
  • Analyst Count
  • CYTH 3
  • NTIP 0
  • Target Price
  • CYTH $3.20
  • NTIP N/A
  • AVG Volume (30 Days)
  • CYTH 42.6K
  • NTIP 20.1K
  • Earning Date
  • CYTH 08-12-2024
  • NTIP 08-08-2024
  • Dividend Yield
  • CYTH N/A
  • NTIP 6.21%
  • EPS Growth
  • CYTH N/A
  • NTIP N/A
  • EPS
  • CYTH N/A
  • NTIP N/A
  • Revenue
  • CYTH $1,126,444.00
  • NTIP $2,064,000.00
  • Revenue This Year
  • CYTH $28.30
  • NTIP N/A
  • Revenue Next Year
  • CYTH $14.19
  • NTIP N/A
  • P/E Ratio
  • CYTH N/A
  • NTIP N/A
  • Revenue Growth
  • CYTH N/A
  • NTIP 284.36
  • 52 Week Low
  • CYTH $0.89
  • NTIP $1.52
  • 52 Week High
  • CYTH $2.12
  • NTIP $2.60
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 40.45
  • NTIP 52.62
  • Support Level
  • CYTH $1.12
  • NTIP $1.56
  • Resistance Level
  • CYTH $1.34
  • NTIP $1.68
  • Average True Range (ATR)
  • CYTH 0.09
  • NTIP 0.07
  • MACD
  • CYTH -0.01
  • NTIP 0.01
  • Stochastic Oscillator
  • CYTH 10.71
  • NTIP 72.22

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

Share on Social Networks: